← Eichor
Study identifier: NCT05914831 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Ultra-hypofractionated for Whole Breast Irradiation (WBI) Compared to Partial Breast Irradiation (PBI)

Condition: Breast Cancer Female  ·  Sponsor: Oncology Institute of Vojvodina

PhasePhase 2
Planned participants100
Who can joinFemale, 50 Years to no upper limit
Healthy volunteersNo

About this study

Female patients undergoing surgical treatment for early breast cancer and meeting the inclusion criteria for adjuvant breast radiotherapy were randomized into two groups. One group will receive adjuvant whole-breast radiotherapy in ultra-hypofractionated regimen of 26 Gy in 5 fractions. In contrast, the other group will receive partial breast irradiation with a dose of 26Gy in 5 fractions. The study's objective is to compare the effects of both breast radiotherapy protocols in terms of locoregional disease control and survival and to compare the adverse effects of radiotherapy between the two protocols. To determine if there is a correlation between different parameters and the efficacy and degree of toxicity for both protocols.

This description comes directly from the study's public registry record.

Talk to the study team

Olivera Ivanov  ·  0214805496  ·  ivanov.olivera@onk.ns.ac.rs

Marko Bojovic  ·  bojovic.marko@onk.ns.ac.rs

Always discuss trial participation with your own doctor first.

Locations (1)

Oncology Institute of VojvodinaNovi Sad, Vojvodina, SerbiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05914831